Fig. 5.

CD45RARO identifies degranulating NK cells. PBMCs from healthy donors (HD) and patients with different hematological malignancies were purified as in Fig. 1. A) Number of CD107a⁺ cells in each NK cell subset (CD45RA RO expression described in Fig. 1A) per million of NK cells. Bars represent the mean ± SD for each medical condition; Student t-test compare to healthy donor samples. B) Percentage of CD107a⁺ NK cells in the four different subsets. C) Upper panels, Percentage of CD107a⁺ cells in different NK cell subsets isolated from bone marrow samples (bms) of patients with MM (shown also the percentage in the corresponding blood sample, bs, for comparison) or AML. Bottom panels, Percentage of CD107a⁺ cells in different NK cell subsets after exposure to target K562 tumor cells (in vitro cytotoxicity assay). PBMCs were incubated for 4 h with target K562 tumor cells at the effector:target ratio of 10:1.